Skip to content

Board of Directors

The members of the Fidelis Board of Directors each bring a wealth of experience in diverse areas of pharmaceutical business to help us best serve the animal health community with high-quality innovative solutions.

Meet Our Board of Directors:

MICHAEL WELLS

Chairman and Chief Executive Officer

Fidelis Chairman of the Board and Chief Executive Officer Michael Wells has extensive pharmaceutical experience and expertise in licensing and commercialization of prescription drugs. He concurrently serves as a managing director at Princeton Biopharma Capital Partners, a boutique private-equity firm he founded in 2010 to provide growth capital and operating expertise to commercial-stage healthcare companies.

Prior to starting Princeton Biopharma, Mr. Wells was founder and CEO of Aton Pharma, Inc, a specialty pharmaceutical company focused on treating rare diseases. For his part in developing Aton, Mr. Wells was recognized as the 2009 Ernst & Young Entrepreneur of the Year. He started Aton in 2004 with a blank piece of paper and a dream, growing it to a company with 11 products sold in 30 countries. Aton was sold to Valeant Pharmaceuticals International for $330 million in 2010.

Mr. Wells also brings eight years of sales and marketing experience with the leading pharmaceutical manufacturer Merck to his roles at Fidelis. After his time at Merck, his first start-up venture was founding Lathian Systems Inc. to provide online data and marketing services to pharmaceutical and biotechnology companies.

In addition to serving on the Fidelis Board of Directors and as a University of Pittsburgh Trustee, Mr. Wells currently holds board positions with Covis Pharma SARL, Valeo Pharmaceuticals, and PhotoSonix Medical. He earned BS and MS degrees from the University of Pittsburgh and an MBA from The Wharton School.

BARRY LEVINSON, PhD

Board Member and Fidelis Co-Founder
A distinguished Princeton- and Yale-educated biochemist, Dr. Barry Levinson serves as a managing director at Princeton Biopharma Capital, and is a Fidelis board member and chief development officer. He has been instrumental in bringing Ethiqa XR® to market throughout the U.S., as well as in securing additional capital for further product development and expansion at Fidelis.
Dr. Levinson’s track record of accomplishments in pharmaceuticals and biotech spans more than 40 years. Prior to co-founding Fidelis, he served as vice president of business development Valeant Pharma (now Bausch Health) and was a founding vice president (business development) and chief scientific officer at Aton Pharma.

Always having an entrepreneurial spirit, Dr. Levinson began his corporate years at the biotech start-up Ecogen. From there, he spent a decade in increasingly senior positions in cardiovascular research and business development for Berlex Labs. He then worked at two consulting firms before joining Aton.

After earning his BA with highest honors in biochemistry from Princeton, Barry went on to earn his MS and PhD degrees in molecular biophysics and biochemistry from Yale University. Mr. Wells also brings eight years of sales and marketing experience with the leading pharmaceutical manufacturer Merck to his roles at Fidelis. After his time at Merck, his first start-up venture was founding Lathian Systems Inc. to provide online data and marketing services to pharmaceutical and biotechnology companies. In addition to serving on the Fidelis Board of Directors and as a University of Pittsburgh Trustee, Mr. Wells currently holds board positions with Covis Pharma SARL, Valeo Pharmaceuticals, and PhotoSonix Medical. He earned BS and MS degrees from the University of Pittsburgh and an MBA from The Wharton School.

ANDREW MIDLER

Board Member
Andrew Midler is the founder and a managing member of Savitr Capital, a healthcare venture investment firm. Previously, he founded Standard Pacific Capital and served as its chief executive officer and chief information officer. During his tenure, the firm grew to more than $5 billion in assets with a global team of 100 people.
Prior to founding Standard Pacific, Mr. Midler served as the director of equity portfolio management at CS First Boston and as a global hedge fund manager for Odyssey Partners. His early career experience included serving as a portfolio manager at Fidelity Investments.

Mr. Midler holds an MBA from Harvard University and MA and BA degrees in political science from Stanford University.

Connect with us

Fidelis is actively seeking new partnerships and product opportunities. If would like to get more information or would like to discuss investment, partnership, or new product development opportunities with the Fidelis leadership team, please contact us below. Thank you for your interest.